Support Material

HyTest Articles

HyTest Articles

Scientific research forms a solid foundation for product development at Hytest. Our scientists regularly publish articles in peer-reviewed journals. We also work actively in IFCC working groups for troponin I and PAPP-A standardizations.
To date, our scientists have either authored or co-authored some 30 articles that were published in peer-reviewed journals.

Go to:

Troponin
B-type natriuretic peptide
IGFBP-4 and PAPP-A
Transferrin receptor
Adiponectin
D-dimer

Troponin

Katrukha AG, et al. (1995) A new method of human cardiac troponin I and troponin T purification. Biochem. Mol. Biol. Int. 36, 195-202.
Katrukha AG, et al. (1997) Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin. Chem. 43(8), 1379-1385.
Katrukha AG, et al. (1998) Degradation of cardiac troponin I: implication for reliable immunodetection. Clin. Chem. 44(12), 2433-2440.
Filatov VL, et al. (1998) Epitope mapping of anti-troponin I monoclonal antibodies. Biochem. Mol. Biol. Int. 45(6), 1179-1187.
Filatov VL, et al. (1999) Troponin: structure, properties, and mechanism of functioning. Biochemistry 64(9), 969-985.
Katrukha A, et al. (1999) New approach to standardisation of human cardiac troponin I (cTnI). Scand. J. Clin. Lab. Invest. Suppl. 230, 124-7.
Katrukha A, et al. (1999) Biochemical factors influencing measurement of cardiac troponin I in serum. Clin. Chem. Lab. Med. 37(11-12), 1091-1095.
Katrukha AG. (2003) Antibody selection strategies in cardiac troponin assays. Cardiac Markers, 2nd edition, Edited by Alan HB. Wu. 173-185.
Panteghini M, et al. (2008) IFCC Working Group on Standardization of Troponin I.Standardization of troponin I measurements: an update. Clin. Chem. Lab. Med. 46(11):1501-1506.
Noble JE, et al. (2010) IFCC Working Group on Standardization of Troponin I (WG-TNI). Development of a candidate secondary reference procedure (immunoassay based measurement procedure of higher metrological order) for cardiac troponin I: I. Antibody characterization and preliminary validation. Clin. Chem. Lab. Med.; 48(11), 1603-1610.
Tate JR, et al. (2010) IFCC Working Group on Standardization of Troponin I. S tandardisation of cardiac troponin I measurement: past and present. Pathology 42(5): 402-408.
Vylegzhanina AV, et al. (2013) Epitope Specificity of Anti-Cardiac Troponin I Monoclonal Antibody 8I-7. Clin. Chem. 59(12), 1814-1816.
Barth JH, et al. (2014) Recommendation to harmonize the units for reporting cardiac troponin results.Clin Chim Acta. 2014 May 15(432):166.
Tate JR, et al. (2015) IFCC Working Group on Standardization of Cardiac Troponin I. Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. Clin. Chem. Lab. Med. 53(5): 677-690.
Vylegzhanina AV, et al. (2017) Anti–Cardiac Troponin Autoantibodies Are Specific to the Conformational Epitopes Formed by Cardiac Troponin I and Troponin T in the Ternary Troponin Complex. Clin. Chem. 63(1), 343-350
Katrukha IA, et al. (2017) Thrombin-Mediated Degradation of Human Cardiac Troponin T. Clin. Chem. 2017 Jun;63(6):1094-1100. doi: 10.1373/clinchem.2016.266635. Epub 2017 Apr 20.
Katrukha IA, et al. (2018) Full-Size Cardiac Troponin I and Its Proteolytic Fragments in Blood of Patients with Acute Myocardial Infarction: Antibody Selection for Assay Development. Clin. Chem. 2018 Jul;64(7):1104-1112. doi: 10.1373/clinchem.2017.286211. Epub 2018 Apr 9.
Vylegzhanina AV, et al. (2019) Full-Size and Partially Truncated Cardiac Troponin Complexes in the Blood of Patients with Acute Myocardial Infarction. Clin. Chem. 2019 Jul;65(7):882-892. doi: 10.1373/clinchem.2018.301127. Epub 2019 Mar 11.
Katrukha IA, et al. (2021) Myocardial Injury and the Release of Troponins I and T in the Blood of Patients. Clin. Chem. 2021 Jan 8;67(1):124-130. doi: 10.1093/clinchem/hvaa281.
Katrukha IA , et al. (2023) Fragmentation of human cardiac troponin T after acute myocardial infarction. Clin Chim Acta. 1;542:117281. doi: 10.1016/j.cca.2023.117281.

B-type natriuretic peptide

Seferian KR,et al. (2007) The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin. Chem. 53, 866-873.
Seferian KR, et al. (2008) Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin. Chem. 54(5), 866-873.
Tamm NN, et al. (2008) Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. Clin. Chem. 54(9), 1511-1518.
Semenov AG, et al. (2009) Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin. Chem. 55(3), 489-498.
Semenov AG, et al. (2010) Processing of Pro-B-Type Natriuretic Peptide: Furin and Corin as Candidate Convertases. Clin. Chem. 56(7), 1166-1176.
Tamm NN, et al. (2011) Measurement of B-type natriuretic peptide by two assays utilizing antibodies with different epitope specificity. Clin. Biochem. 44(2-3), 257-259.
Semenov AG, et al. (2011) Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin. Chem. 57(6), 883-890.
Semenov AG and Seferian KR (2011) Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing. Clin. Chim. Acta 412(11-12), 850-860.
Røsjø H, et al. (2012) Diagnostic utility of a single-epitope sandwich B-type natriuretic peptide assay in stable coronary artery disease: data from the Akershus Cardiac Examination (ACE) 1 Study. Clin. Biochem. 45(16-17), 1269-75.
Semenov AG, et al. (2016) Searching for a BNP standard: Glycosylated proBNP as a common calibrator enables improved comparability of commercial BNP immunoassays Clin. Biochem. 2016 Nov 5. pii: S0009-9120(16)30503-3. doi: 10.1016/j.clinbiochem.2016.11.003
Semenov AG and Katrukha AG (2016) Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter. Clin. Chem. 2016 Apr;62(4):617-22. doi: 10.1373/clinchem.2016.254524. Epub 2016 Feb 10.
Semenov AG and Katrukha AG (2016) Analytical Issues with Natriuretic Peptides - has this been Overly Simplified? EJIFCC. 2016 Aug 1;27(3):189-207. eCollection 2016 Aug.
Semenov AG, et al. (2017) Searching for a BNP standard: Glycosylated proBNP as a common calibrator enables improved comparability of commercial BNP immunoassays. Clin Biochem. 2017 Mar;50(4-5):181-185.
Semenov AG and Feygina EE (2018) Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. In Advances in Clinical Chemistry, pp 1–30, Elsevier.
Semenov AG and Katrukha AG (2019) A View on the Interrelationship Between Obesity and Natriuretic Peptide Measurements: Can Dysregulation in pro–B-type Natriuretic Peptide Glycosylation Explain Decreased B-type Natriuretic Peptide Concentrations in Obese Heart Failure Patients? Clin. Chem. 2019 Jun 24. pii:clinchem.2019.306175. doi:10.1373/clinchem.2019.306175
Feygina EE, et al. (2019) Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure. Clin. Chem. 2019 Jul 15. pii:clinchem.2019.303438. doi:10.1373/clinchem.2019.303438.
Feygina EE, et al. (2019) Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang. Biochemistry (Mosc). 2019 Nov;84(11):1346-1358. doi: 10.1134/S0006297919110105.
Semenov AG (2020) In-Depth Analysis of Molecular Heterogeneity of Circulating N-Terminal pro-BNP: Does Detailed Characterization of Analyte Structure Really Matter for Its Diagnostic Use? Clin. Chem. 2020 Sep 1;66(9):1131-1133. doi: 10.1093/clinchem/hvaa162
Li L , et al. (2022) Diagnostic utility of total NT-proBNP testing by immunoassay based on antibodies targeting glycosylation-free regions of NT-proBNP. Clin Chem Lab Med. 2;61(3):485-493. doi: 10.1515/cclm-2022-1194.

IGFBP-4 and PAPP-A

Postnikov AB, et al. (2012) N-terminal and C-terminal fragments of IGFBP-4 as novel biomarkers for short-term risk assessment of major adverse cardiac events in patients presenting with ischemia. Clin. Biochem. 45:519-24.
Schulz O, et al. (2014) Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease. Clin. Biochem. 47(3):177-83.
Konev AA, et al. (2015) Characterization of endogenously circulating IGFBP-4 fragments—Novel biomarkers for cardiac risk assessment. Clin. Biochem. 48(12): 774-80.
Konev AA, et al. (2018) Glycosylated and non-glycosylated NT-IGFBP-4 in circulation of acute coronary syndrome patients. Clin Biochem. 2018
Konev AA, et al. (2020) CT-IGFBP-4 as a Novel Prognostic Biomarker in Acute Heart Failure. ESC Heart Fail. 2020 Apr;7(2):434-444.
Serebryanaya DV, , et al. (2021). IGFBP-4 Proteolysis by PAPP-A in a Primary Culture of Rat Neonatal Cardiomyocytes under Normal and Hypertrophic Conditions. Biochemistry (Mosc). 86(11):1395-1406. doi: 10.1134/S0006297921110043.
Adasheva DA, et al.(2023) PAPP-A-Specific IGFBP-4 Proteolysis in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Biochemistry (Moscow) 8;24(9):8420. doi: 10.3390/ijms24098420.

Transferrin receptor

Kogan A, et al. (2005) Immunological study of complex formation between soluble transferrin receptor and transferrin. Am. J. Hematol. 79(4), 281-287.
Kogan AE, et al. (2007) Comparison of soluble and placental transferrin receptors as standards for the determination of soluble transferrin receptor in humans. Int. J. Lab. Hematol. 29(5), 335-340.

Adiponectin

Kogan AE, et al. (2013) Oligomeric adiponectin forms and their complexes in the blood of healthy donors and patients with type 2 diabetes mellitus. J Immunoassay Immunochem. 34:2,180-196. doi: 10.1080/15321819.2012.699494

D-dimer

Kogan AE, et al. (2015) Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagul. Fibrinolysis, 2015 Dec 11. [Epub ahead of print] PubMed PMID: 26656897.

Copyright © HyTest Ltd.